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A B S T R A C T
Fasciola hepatica, a zoonotic liver fluke, can also cause disease in humans. Common symptoms are
epigastric pain, upper abdominal pain and malaise. Fever and arthralgia are common in acute
fascioliasis. Eosinophilia is the predominant laboratory finding, especially in patients with the acute
form of the disease. Diagnosis and treatment is not easy, as physicians rarely encounter this disease, and
effective drugs are not available in many countries. Human fascioliasis may be underestimated. Patients
with eosinophilia and abdominal pain should be evaluated for F. hepatica infestation by parasitological,
radiological and serological tests.
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Fascioliasis is a zoonotic disease caused by the
trematode Fasciola hepatica. It can infect a wide
variety of mammalian hosts, particularly sheep,
goats and cattle. Humans become infected after
eating aquatic plants on which encysted organ-
isms are present or by drinking contaminated
water. Over the period 1970–90, 2594 human
cases were reported in 42 countries, and the
World Health Organisation now recognises
fascioliasis as an important disease in humans
[1].
The definitive diagnosis of fascioliasis is based
on the presence of Fasciola eggs in a stool or
gallbladder sample, or on a positive serological
test plus radiological findings indicating fascioli-
asis [2]. Patients are classified according to the
duration of their symptoms and the ultrasono-
graphic findings. If the duration of symptoms is
< 4 months and there are no motile echogenic
images in the gallbladder on admission, it is
classified as acute. If symptoms persist for
> 4 months or there are motile echogenic images
in the gallbladder, it is classified as chronic. If
fascioliasis is defined during investigation for
eosinophilia detected in routine screening, or
during investigation of a patient’s family mem-
bers, it is classified as latent.
Fifty-three cases of human fascioliasis were
diagnosed at the Akdeniz University Hospital,
Infectious Diseases Department in 1998–2003.
This is a 640-bed hospital for patients requiring
specialised medical care in Antalya, southern
Turkey. The mean age of these patients was
42 years (range 9–75 years), with 21 males and 32
females. Thirty-two patients lived in the centre of
Antalya, 14 in the surroundings, and seven both
in Antalya and in the surroundings. Twenty-
eight patients presented with the acute form, 19
with the chronic form, and six with latent
infection. Of these six, one (with fascioliasis
diagnosed by serological testing) was a relative
of two other patients, two were diagnosed
during investigations for eosinophilia detected
in routine screening, and three had ultrasound
examination because of other medical problems.
The commonest symptoms were epigastric pain
(29 patients; 55%), right upper abdominal pain
(20 patients; 38%), and malaise (20 patients;
38%). Fever and arthralgia were statistically
more common in the acute form than in the
chronic form (p 0.02 and p 0.03, respectively).
The main clinical characteristics of the 53
patients are summarised in Table 1. Significant
laboratory and diagnostic data are summarised
in Table 2.
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Triclabendazole tablets (CGP 23030; Novartis,
Basel, Switzerland) 10 mg ⁄kg, one dose post-
prandially, were given to 37 patients, and
20 mg ⁄ kg was given in two divided doses to 13
patients. Two patients refused to take the medi-
cation and went to another hospital, and one
patient underwent surgery only. Before diagnosis
and triclabendazole treatment, five patients
underwent surgery, two patients were treated
with praziquantel, and one patient underwent
endoscopic retrograde cholangiography. Thirteen
patients who were given triclabendazole did not
return; treatment was successful in 30 patients.
Seven patients did not respond to the first course;
two of these had both symptoms and echogenic,
non-shadowing motile particles in the gallblad-
der, three had symptoms only, and the remaining
two had no symptoms, but non-shadowing motile
particles were seen in the gallbladder. Four of the
non-responders were treated successfully with a
second course, and two of the non-responders
were treated with three additional courses. One
did not respond to triclabendazole, but was then
treated successfully with albendazole. The
remaining two patients were given additional
triclabendazole, but did not attend for follow-up.
The drugs were well-tolerated, and only moder-
ate side-effects were seen. Most cases in Turkey
documented previously were found coinciden-
tally with cholecystectomy [3–6], but 47 of our 53
cases were diagnosed without surgery.
F. hepatica infestation has two distinct phases.
The clinical symptoms vary considerably accord-
ing to the phase of the disease [7–10]. The acute or
hepatic phase of the illness occurs when the
organism perforates the liver capsule and begins
to migrate towards the biliary system. The symp-
toms during this phase are related to the destruc-
tion and inflammatory response caused by the
migrating larvae, characterised by fever and pain
in the right upper quadrant. Frequent complaints
during the acute phase were epigastric pain
(16 patients; 57%), fatigue (13 patients; 46%),
fever (12 patients; 43%), and right upper quad-
rant abdominal pain (ten patients; 36%). Four
patients had cough and five had pruritis (two of
these had both pruritis and a cough, which made
diagnosis difficult at presentation). This phase
usually lasts for 3 months after ingestion of the
metacercariae, after which, as the parasite enters
the bile canaliculi, the symptoms may decline or
disappear completely. This second phase is the
biliary or chronic phase. Occasionally, some
patients develop symptoms of biliary obstruction,
frank cholangitis or pancreatitis. Seventeen of our
53 patients presented at the chronic stage of
disease, but none had biliary obstruction. Their
symptoms were mild; 13 (68%) had epigastric
pain, ten (53%) had right upper abdominal
quadrant pain, and eight (42%) had nausea. One
patient had a cough and another patient had
pruritis at presentation.
Only 13 (25%) patients had a history of inges-
tion of watercress. Fascioliasis should always be
considered in patients from endemic areas with a
Table 1. Demographic and clinical symptoms of 53
patients with fascioliasis
Acute
(n = 28)
Latent
(n = 6)
Chronic
(n = 19) p
Sex
Male 16 2 3
Female 12 4 16
Age (years)
Mean 42 ± 16 50 ± 17 50 ± 18 0.28
Clinical symptoms
No 6
Yes 28 19
Fatigue 13 (54%) 7 (37%) 0.56
Epigastric pain 16 (57%) 13 (68%) 0.54
Right upper quadrant pain 10 (36%) 10 (53%) 0.36
Fever 12 (43%) 2 (11%) 0.02a
Nausea 8 (27%) 8 (42%) 0.36
Myalgia 3 (11%) 1 (5%) 0.13
Arthralgia 7 (25%) 0.03a
Weight loss 4 (14%) 2 (11%) 1
Sweating 3 (11%) 1 (5%) 0.13
Pruritis 5 (18%) 1 (5%) 0.37
Cough 4 (14%) 1 (5%) 0.63
Place
Urban area 17 (61%) 5 (83%) 10 (53%) 0.15
Surroundings 5 (18%) 1 (17%) 8 (42%)
Both urban and surroundings 6 (21%) 1 (5%)
ap < 0.05.
Table 2. Laboratory findings and diagnostic methods
used for patients with fascioliasis
Acute
(n = 28)
Latent
(n = 6)
Chronic
(n = 19) p
Laboratory findings
Eosinophilia 28 3 4
Mean count ⁄mm3 5076 ± 3582 3371 ± 4147 404 ± 380 0
Elevated ALT level 13 (46%) 2 (33%) 3 (16%) 0.094
Elevated acute-
phase reactant
15 (54%) 1 (17%) 7 (37%) 0.2
Diagnostic method
Eggs in faeces 1 2
Ultrasound-
guided aspirationa
2 1
Liver sonography 22 5 15
Pathologyb 3 1 2
ELISA test for
parasite antibody
28 6 18c
aFour patients only.
bSix patients only.
cOne patient not tested.
ALT, alanine aminotransferase.
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history of ingestion of aquatic plants. However,
lack of such a history does not rule out infection,
because there is also evidence that infection can
be acquired by drinking contaminated water
[11,12].
Diagnosis may be problematical and delayed
because physicians rarely encounter this disease
and a long list of other diseases must be
included in the differential diagnosis. During
the acute phase, stool studies for ova are
unhelpful, since the parasites cannot produce
eggs before invasion of the biliary tree [7–9].
Negative stool examinations do not rule out
fascioliasis. Serological tests for F. hepatica E-S
antigens are useful in establishing an early
diagnosis [12–14]. Radiological findings are also
helpful [2,15–17]. As indicated above, the clinical
spectrum of fascioliasis is variable, but eosino-
philia is the most frequent laboratory abnormal-
ity in acute cases.
Triclabendazole, given as a single oral dose of
10 mg ⁄kg or, in cases of severe infection,
20 mg ⁄kg divided into two doses, is the drug of
choice for the treatment of F. hepatica infestations
[18]. A patient can respond to treatment even
when there is obstruction of the biliary system
[11]. The cure rate among our own patients was
78%, and the addition of another course(s)
increased this to 90%. No significant side effects
have been reported to date, but this drug may not
be readily available in many countries, including
Turkey.
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